clinical trial · NCT04990284
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
Bial - Portela C S.A.·phase4·completed·n = 106
Parkinson DiseaseOpicaponeL-DOPA/DDCI
brief summary
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa (L-DOPA) 100 mg as first strategy for the treatment of wearing-off.
started
Nov 29, 2021
primary completion
Apr 4, 2023
completion
Apr 4, 2023
last updated
Mar 12, 2025
detailed description
The study consists of a one-week screening period, four weeks of open-label treatment and two weeks of post-study follow-up. The total study duration for each patient will be approximately 7 weeks
official title
A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study to Evaluate the add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol